Human urotensin-II (hU-II) is processed from its prohormone (ProhU-II) at putative cleavage sites for furin and serine proteases such as trypsin. Although proteolysis is required for biological activity, the endogenous "urotensin-converting enzyme" (UCE) has not been investigated. The aim of this study was to investigate UCE activity in cultured human cells and in blood, comparing activity with that of furin and trypsin. In a cell-free system, hU-II was detected by high-performance liquid chromatography-mass spectrometry after coincubating 10 M carboxyl terminal fragment (CTF)-ProhU-II with recombinant furin (2 U/ml, 3 h, 37°C) at pH 7.0 and pH 8.5, but not at pH 5.0, or when the incubating medium was depleted of Ca 2ϩ ions and supplemented with 2 mM EDTA at pH 7.0. hU-II was readily detected in the superperfusate of permeabilized epicardial mesothelial cells incubated with CTF-ProhU-II (3 h, 37°C), but it was only weakly detected in the superperfusate of intact cells. Conversion of CTF-ProhU-II to hU-II was attenuated in permeabilized cells using conditions found to inhibit furin activity. In a cell-free system, trypsin (0.05 mg/ml) cleaved CTFProhU-II to hU-II, and this was inhibited with 35 M aprotinin. hU-II was detected in blood samples incubated with CTFProhU-II (3 h, 37°C), and this was also inhibited with aprotinin. The findings revealed an intracellular UCE in human epicardial mesothelial cells with furin-like activity. Aprotinin-sensitive UCE activity was detected in blood, suggesting that an endogenous serine protease such as trypsin may also contribute to proteolysis of hU-II prohormone, if the prohormone is secreted into the circulation.
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Human urotensin-II (hU-II) is an endogenous peptide ligand that interacts with the recently cloned human G protein-coupled receptor UT-II. The UT-II receptor system is ubiquitously expressed in mammalian tissues, including heart, lungs, blood vessels, kidney, and brain. The vascular effects of receptor stimulation include contraction of isolated endothelium-denuded arteries (Maguire et al., 2000; Russell et al., 2001 ) and veins (Maguire et al., 2000) , and endotheliumand nitric oxide-dependent relaxation of small human pulmonary and rat renal arteries (MacLean et al., 2000; Zhang et al., 2003) . Infusion of hU-II into the renal artery of anesthetized rats caused an increase in renal blood flow (Zhang et al., 2003) , consistent with relaxation of the isolated renal artery preparation. In humans, intrabrachial artery infusion of hU-II either reduced (Böhm and Pernow, 2002) or had no effect (Wilkinson et al., 2002) on forearm blood flow. Infusion of hU-II into anesthetized monkeys caused cardiodepression (Ames et al., 1999) , possibly secondary to massive vasoconstriction because hU-II caused positive inotropy in isolated human right atrial and ventricular strips (Russell et al., 2001) .
Two alternative splicing variants of human prohormone (prepro-hU-II), consisting of 124-and 139-amino acid residues, have been cloned and these were found to differ only in their amino terminus (Coulouarn et al., 1998; Ames et al., 1999) . The conserved, carboxyl terminus of the prohormone is cleaved to produce a mature, 11-amino acid residue peptide. The potency of this mature peptide was markedly higher than a larger C-terminal fragment of the prohormone (CTF-ProhU-II; Russell et al., 2003) , suggesting that proteolytic cleavage is required for biological activity. Despite this requirement, the pathways leading to the production of hU-II are poorly understood. For example, it is not known which cells contain enzymes that may contribute to proteolytic cleavage of the prohormone, or whether this processing occurs at the cell surface or intracellularly.
Direct evidence for the expression of a "urotensin-converting enzyme" was demonstrated in porcine renal tissue using a mass spectrometry-assisted enzyme screening system (Schlü ter et al., 2003) , although the identity of the convertase involved was not investigated. Multiple high-molecularweight urotensin-II-like peptides were extracted from the superperfusate of cultured SW-13 adrenocortical carcinoma cells, indicating possible proteolytic processing of the prohormone by these cells ). More recently, molecular biology techniques revealed localization of prepro-U-II mRNA in mammalian cells, including human vascular smooth muscle cells (Douglas et al., 2002) , endothelial cells (Douglas et al., 2002; Totsune et al., 2003) , endocardial endothelial cells (Douglas et al., 2002) , and motoneurons (Coulouarn et al., 1998) , and rat cardiac fibroblasts (Tzanidis et al., 2000) . It remains to be determined whether the prohormone is processed locally within these cells or is secreted and processed at a remote location.
Putative post-translational cleavage sites have been identified within the urotensin-II prohormone, including multiple mono-and polybasic amino acid residues (Conlon et al., 1990; Douglas and Ohlstein, 2000) . It is interesting to note that the R 12 -K 13 -K 14 -Y 15 -P 16 -K 17 amino acid sequence of the urotensin-II prohormone also conforms to stringent rules that govern the efficiency of convertase activity by furin, an enzyme that is expressed primarily in the trans-Golgi network of most cell types, and with a role in proteolytic cleavage of a large number of prohormones (Nakayama, 1997) .
The circulation may present an alternate site for urotensin-converting enzyme activity. Urotensin-II-like immunoreactivity has been detected in blood from healthy individuals and patients with renal and cardiovascular disease (Totsune et al., , 2003 Richards et al., 2002; Russell et al., 2003) . However, antibodies used in the detection of mature hU-II cross-reacted with CTF-ProhU-II (Russell et al., 2003) , raising the possibility that full-length, or partially processed prohormone might contribute to immunoreactivity detected in blood. Monobasic and dibasic residues form common recognition sequences for broad range peptide and protein convertases. In this study, we focus on the enzymatic activity of trypsin, an enzyme present in serum of normal healthy individuals (Le Moine et al., 1994) and whose substrate specificity for X 1 -K 2 and X 1 -R 2 bonds would be predicted to cleave between the E 11 -R 12 residues of prohU-II. The aim of this study was to investigate UCE activity in cultured human cells and in blood, comparing activity to that of furin and trypsin. Queensland (2001002160; 2002000008) . Forearm venous blood samples were obtained from healthy volunteers.
Materials and Methods

Collection of
Cell Culture. Right atrial appendages were immersed in Hanks' buffered saline solution containing 0.25% trypsin and 1 mM EDTA (30 min, room temperature), and mesothelial cells were dislodged from the epicardium using a cell scraper. The cell suspension was spun (230g, 6 min, 4°C), the pellet was resuspended in Dulbecco's modified Eagle's medium containing 20% fetal bovine serum, penicillin (100 U/ml), and streptomycin (0.1 mg/ml) (20% DMEM solution), and plated into six-well plates. Cryostat cut sections (20 m) of the atrium were collected on microscope slides and stained with cresyl violet to verify removal of epicardial mesothelial cells. The atrial appendage was scraped vigorously with a scalpel blade to remove any residual mesothelium, and blocks of epicardium (Ϸ0.5 mm 3 ) were transferred into six-well plates and incubated in 10% DMEM solution. After 2 to 3 weeks, blocks of tissue were removed from the plates and fibroblasts, which had proliferated from the blocks, were collected using trypsin-versene mixture (Cambrex Bio Science Rockland, Inc., Rockland ME). The fibroblast cell suspension was spun (230g, 6 min, 4°C), and the pellet was resuspended in 10% DMEM solution and plated into six-well plates.
Umbilical veins from human umbilical cords were cannulated with a blunt end needle and flushed with DMEM to remove blood. The noncannulated end of the cord was clamped and DMEM containing 1 mg/ml collagenase IV was administered into the vein and incubated for 30 min at room temperature. The cell suspension was collected, spun (230g, 6 min, 4°C), resuspended in 20% DMEM solution, and plated into six-well gelatin coated (2.5 mg/ml) plates.
Primary cultures of all cell types were used to minimize phenotypic changes, and cells were grown to confluence in a 5% CO 2 incubator. Culture medium was changed every 3 days. Cells were also grown on gelatin-coated glass coverslips for immunocytochemistry. Mesothelial cells stained positively with a mouse monoclonal antibody to cytokeratin 18 (clone B23.1; 1:100; Abcam, Cambridge, UK), fibroblasts with a mouse monoclonal antibody to SM1214 (clone D7-FIB; 1:500; DPC Biermann, Bad Nauheim, Germany), and endothelial cells with a mouse monoclonal antibody to von Willebrand factor (clone F8/86; 1:100; DakoCytomation Denmark A/S, Glostrup, Denmark). Fibroblasts stained negatively with a mouse monoclonal antibody to smooth muscle ␣-actin (clone 1A4; 1:1000; Immunon, Pittsburgh, PA). Immunoreactivity was detected using an anti-mouse IgG Texas Red conjugate (20 g/ml; Molecular Probes, Leiden, The Netherlands), and viewed using an Olympus CK2 inverted microscope.
Biochemical Studies. CTF-ProhU-II (10 M; Auspep, Parkville, Australia) was incubated for 3 h at 37°C in incubation medium containing Tris HCl (100 mM; pH 5.0, 7.0, or 8.5) and CaCl 2 (1 mM), with or without furin (2 U/ml; New England BioLabs, Beverly, MA), trypsin (0.05 mg/ml, type XI; Sigma-Aldrich, St. Louis, MO), or Triton X-100 (0.1%). Samples containing furin were incubated with or without medium that was depleted of Ca 2ϩ ions and supplemented with 2 mM EDTA, whereas samples containing trypsin were incubated in the absence or presence of 34.5 M aprotinin.
In a separate series of experiments, confluent cultured human epicardial mesothelial cells (n ϭ 3), vascular endothelial cells (n ϭ 4), and cardiac fibroblasts (n ϭ 3) (2 wells/treatment) were incubated with CTF-prohU-II (10 M) in incubation medium containing Tris HCl (100 mM; pH 5.0, 7.0, or 8.5), with or without CaCl 2 (1 mM) and EDTA (2 mM). Cells were coincubated in the absence (nonpermeabilized cells) or presence of 0.1% Triton X-100 (permeabilized cells) for 3 h at 37°C.
Blood collected from healthy individuals (n ϭ 3) was immediately incubated with CTF-ProhU-II (25 M) and Tris HCl (100 mM, pH 7.0) in the absence or presence of 34.5 M aprotinin and 0.1% Triton X-100. A sample of freshly collected blood was also spun (1600g, 15 min, 4°C), plasma was collected and incubated with CTF-ProhU-II (25 M) and Tris HCl (100 mM, pH 7) in the absence or presence of 34.5 M aprotinin. Control experiments were carried out in the absence of CTF-ProhU-II.
All samples were loaded onto Sep-Pak C18 cartridges (Waters, Taunton, Ireland), which were preequilibrated with 0.1% trifluoro-acetic acid (10 ml, solvent A), 90% acetonitrile in 0.1% trifluoroacetic acid (10 ml, solvent B), and 10 ml of solvent A. Samples were washed with 3 ml of solvent A and eluted with a 2:3 ratio mixture of solvents A and B. The samples were evaporated to dryness in a Savant Speed Vac SC210a and then reconstituted with solvent A (0.1 ml) for high-performance liquid chromatography (HPLC)-mass spectrometry analysis.
Liquid Chromatography-Mass Spectrometry. Gradient highperformance liquid chromatography analyses were performed on an Agilent SB-C18 (2.1 ϫ 50-mm) column at a flow rate of 0.3 ml/min. The gradient used was solvent A (100%, 2 min), and then ramped from 100% solvent A to 80% solvent B over 8 min, held at 80% solvent B for 2 min, and then returned to 100% solvent A in 6 s. The column was finally washed with 100% solvent A for a further 6 min. Solvents for the binary gradient were delivered with Shimadzu LC10 AT VP liquid chromatography pumps that were controlled with a SCL10A VP Shimadzu system controller. Solvents were degassed with a DGU12A Shimadzu degasser, and samples were introduced to the column using an Agilent 1100 series auto injector. Detection was achieved using a PE Sciex API3000 liquid chromatography-tandem mass spectrometry system. Samples were ionized by positive ion electrospray atmospheric pressure ionization. The ion spray, orifice (O r ) and ring voltages were 5200, 35, and 225 V, respectively. The quadrupole zero (Q o ) voltage was Ϫ10 V, and the declustering potential was 45 V (O r ϪQ o ).
An authentic sample of synthetic hU-II (Auspep) was analyzed by liquid chromatography-mass spectrometry, and the retention time of hU-II was found to be 6.7 min (Fig. 2) . hU-II was detected as a doubly charged ion (m/z 694.4 [M ϩ 2H] 2ϩ ). An extracted ion chromatogram (m/z 693-696) was generated to define the hU-II peak. The hU-II peak was integrated to allow semiquantitative determination of hU-II (Fig. 3) , and the area data were expressed as total ions counted. The sensitivity of detection for hU-II and CTF-ProhU-II was 1 pmol.
Results
Investigation of Furin and Trypsin in the Proteolytic Processing of CTF-ProhU-II. The proteolytic processing of prepro-hU-II was investigated by determining the formation of mature hU-II peptide from a 25-amino acid residue, carboxy terminal sequence that is conserved in the full-length prohormone splice variants (CTF-ProhU-II; Fig.  1 ). CTF-ProhU-II and hU-II were separated using high-performance liquid chromatography, with retention times of 5.9 and 6.7 min, respectively ( Fig. 2A) . The mass-to-charge ratios (m/z) for CTF-ProhU-II and hU-II, determined using mass spectrometry were 634.2 ([M ϩ 5H] 5ϩ ) and 694.4 ([M ϩ 2H] 2ϩ ), respectively (Fig. 2, B and C) . Semiquantitative analysis of hU-II levels in cell-free and biological samples was determined after generation of an extracted ion chromatogram (m/z 693-696; Fig. 3 ).
In a cell-free system, furin and trypsin cleaved CTFProhU-II to produce mature hU-II peptide. The processing of CTF-ProhU-II by furin was pH-dependent, with efficient converting enzyme activity evident at pH 7.0 (Fig. 4) and pH 8.5 (Fig. 4) , but not at pH 5.0 (Fig. 4) . Proteolytic conversion of CTF-ProhU-II was markedly reduced at pH 7.0 when the incubation buffer was depleted of Ca 2ϩ ions and supplemented with 2 mM EDTA (Fig. 4) . CTF-ProhU-II was also cleaved by trypsin (Fig. 4) , and this was sensitive to the trypsin inhibitor aprotinin (Fig. 4) .
UCE Resembles Furin-Like Activity in Vascular and Cardiac Cells.
Expression of a cell surface urotensin-IIconverting enzyme was investigated by measuring the conversion of CTF-ProhU-II to hU-II by cultured, nonpermeabilized human epicardial mesothelial cells, cardiac fibroblasts, and umbilical vein endothelial cells. Only low levels of mature hU-II were detected in the superperfusate of mesothelial cells (Fig. 5) , fibroblasts (not shown) and endothelial cells (not shown), suggesting that an ectoenzyme is not a major contributor to prohormone processing by these cells. However, hU-II was readily detected in cell superperfusates when cells were incubated with CTF-ProhU-II and permeabilized with 0.1% Triton X-100 (Fig. 5) . hU-II was not detected when permeabilized cells were incubated without CTF-ProhU-II (Fig. 5) and was only weakly detected in a cell-free system in which prohU-II was incubated with 0.1% Triton X-100 (Fig.  5) , suggesting that mature peptide was not released from intracellular compartments after cell permeabilization and that the presence of hU-II could not be attributed to spurious cleavage of CTF-ProhU-II by the cell permeabilization procedure.
Consistent with the characteristics of the activity of recombinant furin, the intracellular urotensin-converting enzyme was inhibited, although not abolished under low pH conditions (pH 5.0; Fig. 5) , and by the substitution of incubation medium that was depleted of Ca 2ϩ ions and supplemented with EDTA (Fig. 5) . The partial insensitivity of enzymatic activity to these conditions may also indicate redundancy with respect to intracellular urotensin-converting enzymes.
Evidence for Trypsin-Like UCE Activity in the Circulation. hU-II was readily detected in samples of whole blood that were incubated with CTF-ProhU-II (Fig. 6 ). hU-II was not detected in blood incubated without ProhU-II (not shown), consistent with the low sensitivity of detection of mass spectrometry for endogenous hU-II in blood from individuals with nonfailing hearts. Processing of CTF-ProhU-II by whole blood was sensitive to aprotinin, suggesting the presence of a trypsin-like serine protease in the circulation that is capable of processing the prohormone (Fig. 6 ). Similar findings were obtained when CTF-ProhU-II was incubated with plasma (not shown), indicating that the circulating urotensin-converting enzyme was not associated with erythrocytes.
HU-II-Like Immunoreactive Staining in Human Epicardial Mesothelial Cells.
Cultured human epicardial mesothelial cells were positively identified using the mesothelial cell marker anti-cytokeratin 18 (Fig. 7A) . Positive staining for anti-hU-II peptide was observed in the cytoplasm of the cultured cells, in the perinuclear region (Fig. 7B) . Negligible levels of staining were detected over the nucleus (Fig. 7B ) and in control cells incubated without antibody (Fig.  7C) .
Discussion
Proteolytic cleavage of prohU-II is required for biological activity (Russell et al., 2003) , and so the aim of this study was to investigate urotensin-converting enzyme activity in cultured human epicardial mesothelial cells, vascular endothelial cells, and cardiac fibroblasts, and in whole blood and plasma samples, comparing activity with that of furin and trypsin. Proteolytic enzyme activity was investigated by examining the conversion of a 25-amino acid C-terminal fragment of prohU-II (CTF-ProhU-II) to mature peptide.
Multiple putative post-translational cleavage sites have been identified within preprohU-II (Conlon et al., 1990; Douglas and Ohlstein, 2000) , including a pair of basic amino acid residues, R 12 -K 13 positioned at the convertase site. Although dibasic residues are a common recognition sequence for broad range peptide and protein convertases, it is interesting to note that the E 11 -R 12 -K 13 -K 14 -Y 15 -P 16 -K 17 amino acid sequence of the prohormone also conforms to stringent rules that govern efficient prohormone convertase activity of furin: an Arg residue at P 1 (R 12 ), basic residues in at least two positions corresponding to P 2 , P 4 and P 6 (K 13 , K 17 ), and a nonhydrophobic aliphatic side chain at P 1 Ј (E 11 ) (Nakayama, 1997). Furin is a ubiquitously expressed enzyme in mammalian cells, primarily localized to the trans-Golgi network, and with a role in endoproteolysis of a number of precursor hormones (Nakayama, 1997) . We predicted that prohU-II would be a substrate for furin, a hypothesis supported by our observation that in a cell-free system, recombinant furin cleaved CTF-ProhU-II to mature hU-II. Furin has a requirement for Ca 2ϩ ions (optimal concentration is 1.0 Fig. 3 . Illustration of the procedure used for semiquantitative determination of hU-II present in the biological samples. hU-II eluted from the column with a retention time of 6.7 min (arrow, A), consistent with authentic hU-II (Fig. 2 ). An extracted ion chromatogram (m/z 693-696) was generated to define the hU-II peak (B), and this was integrated to determine the amount of hU-II in the sample. The presence of hU-II, detected as a doubly charged ion (monoisotopic
) was confirmed by mass spectrometry (C). The xaxis was expanded to reveal peaks for mϩ 13 C/z, 694.9 and mϩ2. 13 C/z, 695.4. Fig. 4 . Relative amount of hU-II formed from CTF-ProhU-II in a cell free-system, determined by mass spectrometry. hU-II was detected after incubation of CTF-ProhU-II with 2U/ml furin at pH 7.0 and pH 8.5 (not shown), but not at pH 5.0, or at pH 7.0 in Ca 2ϩ -depleted/ EDTA-supplemented medium. hU-II was readily detected in cell-free medium containing CTF-ProhU-II, which was incubated with 0.05 mg/ml trypsin, but was undetected after coincubation with trypsin and 34.5 M aprotinin. Data are expressed as total number of ions counted over the period of the hU-II peak. Values are mean Ϯ S.E.; n ϭ 3; ‫,ءء‬ P Ͻ 0.01.
Fig. 5.
Relative amount of hU-II formed from CTF-ProhU-II in mesothelial cell cultures and in a cell free-system, determined by mass spectrometry. hU-II was at the limit of detection in nonpermeabilized mesothelial cell superperfusates at pH 7.0, but it was readily detected in cells permeabilized with 0.1% Triton X-100. hU-II was not detected in permeabilized cells incubated without CTF-ProhU-II, and it was detected, albeit at low levels, when CTF-ProhU-II was incubated with Triton X-100 in a cell-free system. Formation of hU-II was attenuated, but not abolished in permeabilized mesothelial cells incubated at pH 5.0, and at pH 7.0 in Ca 2ϩ -depleted/EDTA-supplemented medium. Data are expressed as total number of ions counted over the period of the hU-II peak. Values are mean Ϯ S.E.; n ϭ 3; ‫,ءء‬ P Ͻ 0.01; ‫,ءءء‬ P Ͻ 0.001. jpet.aspetjournals.org Downloaded from mM) and is inactive in Ca 2ϩ -free medium and is inhibited by 2.0 mM EDTA (Molloy et al., 1992) . Optimal furin activity was observed in the pH range 7.0 to 8.5, with little or no activity at pH 5.0 (Molloy et al., 1992) . In the cell-free system in this study, recombinant furin cleaved CTF-ProhU-II at pH 7.0 and 8.5, but it was markedly reduced at pH 5.0. At pH 7.0, conversion of CTF-ProhU-II was also markedly reduced using medium supplemented with 2.0 mM EDTA and depleted of Ca 2ϩ ions, consistent with the previously described characteristics of furin activity.
Proteolytic conversion of CTF-ProhU-II to hU-II was attenuated, although not abolished in permeabilized cells under conditions designed to inhibit furin activity. This finding suggested that although furin may cleave the urotensin-II prohormone in cells, other intracellular enzymes capable of processing the prohormone might contribute to the observed UCE activity. A limitation of the study is that permeabilization of cells with Triton X-100 caused disruption to cell surface and all intracellular membranes, resulting in exposure of CTF-ProhU-II to intracellular enzymes that may not otherwise come in contact with the endogenous prohormone. However, furin has a critical role in the processing of many prohormones during their transit to the cell surface (Nakayama, 1997), and it is likely that the urotensin-II prohormone would also traverse the trans-Golgi network. Consistent with this hypothesis, positive immunoreactive staining for hU-II was observed in the perinuclear region of epicardial mesothelial cells.
Urotensin-II-like immunoreactivity has been detected by radioimmunoassay or enzyme-linked immunosorbent assay in human plasma (Heller et al., 2001; Totsune et al., 2001 Totsune et al., , 2003 Ng et al., 2002; Richards et al., 2002; Russell et al., 2003) ; however, it is not known to what extent, if any, the prohormone or fragments of the prohormone contribute to this immunoreactivity. The ability of hU-II antibodies to cross-react with CTF-ProhU-II (Russell et al., 2003) raised the possibility that the prohormone or fragments of the prohormone might be secreted into the circulation, as has been shown for other peptide systems, for example, endothelin (endothelin-1, big endothelin-1; Neri Serneri et al., 2000) , adrenomedullin (proadrenomedullin N-terminal 20 peptide; Samson, 1998) , and brain natriuretic peptide (BNP-32, highmolecular-weight BNP, NT-proBNP; Hunt et al., 1997) . Although elevated plasma levels of hU-II-like immunoreactivity were detected by radioimmunoassay in patients with congestive heart failure compared with patients with nonfailing hearts, mature hU-II was not detected using mass spectrometry (Russell et al., 2003) , raising the possibility that the antibody recognized a circulating prohormone, a prohormone fragment, or a distinct peptide with sequence similarity to hU-II. Interestingly, cDNA encoding a "urotensin-II-related peptide" was recently cloned from rat, mouse and human, where the putative convertase site also contained dibasic amino acid residues (Sugo et al., 2003) . Although overall amino acid sequence homology was only 18.8% between preprohU-II and the urotensin-II-related peptide, high sequence homology was observed in the C-terminal region that is crucial for both biological activity and immunochemical studies.
If prohU-II is secreted into the circulation, proteolytic conversion is unlikely to occur at the intimal surface of blood vessels because only very modest levels of hU-II were detected in the superperfusate of cultured, nonpermeabilized endothelial cells that were incubated with CTF-ProhU-II (this study). We therefore investigated the possible cleavage of CTF-ProhU-II in blood, focusing on the enzymatic activity of trypsin, whose substrate specificity for X 1 -K 2 and X 1 -R 2 bonds would be predicted to cleave between the E 11 -R 12 residues of prohU-II. Trypsinogen, an inactive zymogen is secreted from the pancreas into the gut where it is converted to trypsin by enterokinase. Trypsin is present within the serum of normal healthy individuals, where the activity is about 80 units/l (Le Moine et al., 1994) . The ability of trypsin to produce mature peptide from CTF-ProhU-II was demonstrated in the present study using a cell-free system, where proteolytic processing was sensitive to the trypsin inhibitor aprotinin. In blood, CTF-ProhU-II was converted to hU-II, and this was also sensitive to inhibition by aprotinin, raising the possibility that a serine protease such as trypsin may be an endogenous, circulating urotensin-II converting enzyme. Processing of CTF-ProhU-II was independent of erythrocytes because similar findings were also observed for samples of plasma.
In conclusion, this study investigated the characteristics of the urotensin-converting enzyme in human epicardial mesothelial cells, vascular endothelial cells, and cardiac fibro- Fig. 6 . Relative amount of hU-II formed from CTF-ProhU-II in venous blood that was obtained from healthy individuals, determined by mass spectrometry. hU-II was detected in whole blood incubated with CTFProhU-II. Formation of hU-II was attenuated but not abolished in blood incubated with CTF-ProhU-II in the presence of 34.5 M aprotinin. Data are expressed as total number of ions counted over the period of the hU-II peak. Values are mean Ϯ S.E.; n ϭ 3; ‫,ء‬ P Ͻ 0.05. jpet.aspetjournals.org blasts and in human whole blood and plasma samples by examining conversion of a C-terminal fragment of prohU-II to hU-II using HPLC-mass spectrometry. The findings revealed that cells contained an intracellular enzyme with furin-like characteristics capable of processing CTF-ProhU-II to hU-II. Only very modest converting enzyme activity was detected on the cell surface. hU-II was detected in blood samples incubated with CTF-ProhU-II, and this was inhibited with aprotinin, suggesting that an endogenous serine protease such as trypsin may also contribute to proteolysis of prohU-II, if the prohormone is secreted into the circulation.
